Rare diseases
Investigational molecules
Locations
Placa Del Pla Del Mestre 7, 08540 Centelles, Spain
Eap Osona Sud Alt Congost S.L.P. in Centelles, Spain specialises in clinical trials of conditions such as COVID-19, Hypercholesterolaemia, Arteriosclerosis, Hypertension, and other specialisations. This site conducts important research.
At Eap Osona Sud Alt Congost S.L.P. in Centelles, clinical research in virus diseases and bacterial infections and mycoses focuses on preventing and treating common infections such as COVID-19, cytomegalovirus infection, respiratory syncytial virus infections, herpes zoster, and acute vulvovaginal candidiasis. These studies are designed to assess vaccine protection, immune response, and the effectiveness and safety of new anti-infective therapies.
The site’s family medicine setting supports research that is closely tied to everyday patient care, with a strong emphasis on prevention and practical infection management.
Research in cardiovascular diseases and nutritional and metabolic diseases covers atherosclerotic cardiovascular disease, hypertension, hypercholesterolemia, hyperlipidemia, and elevated lipoprotein(a). The trials aim to reduce cardiovascular risk, improve cholesterol control, and evaluate whether new therapies can lower the chance of major heart and vascular events.
These studies reflect a broad effort to improve long-term cardiovascular prevention in adults at elevated risk.
Within respiratory tract diseases and immune system diseases, the site is involved in studies of asthma and infection-related immune protection. The research includes evaluating inhaled treatment tolerability for asthma and examining how vaccines and boosters support immune responses in different age groups.
This area brings together chronic respiratory care and immunization research, both important for primary care populations.
Clinical trials at this hospital/clinic also address chronic kidney disease alongside metabolic and blood pressure-related conditions. The main goal is to explore whether new treatments can better protect kidney function, support blood pressure control, and reduce the burden of long-term cardiometabolic disease.
These trials highlight the site’s role in studies aimed at slowing disease progression and improving day-to-day health outcomes.
Clinical trials currently enrolling participants at this site.
Study of Brenipatide (LY3537031) in Adults with Major Depressive Disorder to Evaluate Delay of Relapse Compared with Placebo
SpainA study testing molnupiravir in adults with COVID-19 who are not hospitalized and are at high risk for serious illness
SpainStudy of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk
SpainEfficacy and safety of the investigational mRNA influenza vaccine gskvx000000077430 (drug combination) in adults ≥ 65 years
SpainEfficacy, safety and dose‑response of once‑weekly subcutaneous UBT251 compared with semaglutide in adults with type 2 diabetes
SpainEffect of laroprovstat/rosuvastatin combination versus laroprovstat, rosuvastatin, and placebo on LDL‑C in hypercholesterolemia patients not previously treated with lipid‑lowering therapy
SpainSpainA study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.
SpainStudy on the Effects and Safety of MK-0616 for Adults with High Cholesterol
SpainStudy on the Safety and Immune Response of RSVPreF3 OA Vaccine with PCV20 in Adults Aged 60 and Older with RSV Disease
SpainStudy on the Immune Response and Safety of RSVPreF3 OA Vaccine in Adults Aged 60+ with Respiratory Syncytial Virus Infections
SpainStudy on the Safety of Salbutamol Inhalers with Propellants HFA-152a and HFA-134a for Adults with Asthma
SpainMove up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.
See the offer for sitesTell us about your condition – we search every trial in Europe and connect you with the right site.
